Opioid Use Disorder Treatment Market is anticipated to reach US$ 8.4 billion by 2033, at a CAGR of 10.5%

The Global Opioid Use Disorder Treatment Market is expected to experience remarkable growth during the forecast period, with an estimated value of US$ 3.07 billion in 2023 and US$ 8.4 billion by 2033, growing at a CAGR of 10.5%. In order to expand their customer base, drug abuse treatment providers and manufacturers focus on creating awareness about the harmful effects of drug abuse and the importance of seeking treatment through various media such as television advertisements, newspapers, and information brochures.

The collaboration of organizations, such as GlaxoSmithKline and 2morrow Inc. in March 2016, or GlaxoSmithKline’s agreement with Amneal Pharmaceuticals LLC in August 2013 to distribute generic versions of Suboxone to addiction treatment centers, will benefit the market in the long run. However, the need to invest in integrated research and development activities, and the rising cost of treatment processes are major challenges facing the market.

Request a report sample to gain comprehensive insights@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16561

Despite these challenges, rising prevalence of diseases that cause chronic pain, interest in extended-release formulations, and increasing focus on abuse-deterrent formulations by generic manufacturers are expected to propel market growth. Additionally, various publicly and privately funded programs for opioid use disorder treatment in countries like the United Kingdom, and the adoption of merger and acquisition strategies by several companies to expand their market presence or add new products and services to their existing platforms, are also expected to contribute to market growth. For instance, in December 2015, Acadia Healthcare’s acquisition of Priory Group was intended to expand their capacity and geographic presence in the United Kingdom, which will ultimately contribute to the growth of the overall market for opioid use disorder treatment.

Key Takeaways

• North America is predicted to dominate the industry by the end of the forecast period, with a market share of over 48%.
• Throughout the forecast period, the East Asian market is expected to grow at the quickest rate of 8.8%.
• Buprenorphine is expected to account for 81.4% of the market by the end of the forecast period.
• Hospitals are predicted to dominate the market by distribution channel, accounting for 35% of the market by 2033.

“Rising collaborations and mergers between companies, increasing research and development activities and adoption of technological advanced techniques for treating Opioid disorder will drive the industry’s growth,” comments an FMI analyst

Ask Our Analyst More About Report@ https://www.futuremarketinsights.com/ask-question/rep-gb-16561

Competitive Landscape

The Opioid use disorder treatment Market is competitive and consists of several major players. Major players are creating novel delivery systems for the treatment of opioid use disorder. This is expected to propel Opioid use disorder treatment market. The major players in the market are: Trevena, Opiate Pharmaceutical, Aphios, Kyowa kirin, Gamida-Cell, Novartis, Titan Pharmaceuticals, Inc., Hikma Pharmaceuticals, MediciNova, Alkermes, Inc., BioDelivery Sciences International, Inc.

Some recent developments in the market are:

• In January 2022, Trevena, Inc. declared that China’s National Medical Products Administration (NMPA) has accepted the submission of a New Drug Application (NDA) for OLINVYK (oliceridine) injection, a novel IV analgesic that has been approved in the United States by the FDA for use in adults for managing acute pain severe enough to require an intravenous opioid analgesic.
• In October 2021, Esteve Pharmaceuticals received authorisation from the United States Food and Drug Administration (FDA) for SEGLENTIS (celecoxib and tramadol hydrochloride) for the management of acute pain in adults that is extreme enough to require an opioid analgesic.
• In January 2020, Titan Pharmaceuticals, Inc. made a revelation that they had entered into an agreement with AllianceRx Walgreens Prime for the expansion of accessibility of patients for Titan’s opioid use disorder implant branded as “Probuphine implant”.

More Valuable Insights Available

North America is the largest opioid use disorder market. The region has the highest prevalence of opioid addiction in the world, which has led to an increase in the demand for opioid use disorder treatments. The United States is the largest market in the region, accounting for a significant share of the market.

For in-depth competitive analysis, Buy Now@ https://www.futuremarketinsights.com/checkout/16561

Key Segments Profiled in the Opioid Use Disorder Treatment Market Survey

By Drug Type:

• Romiplostim
• Omidubicel
• Nalmefene
• Buprenorfine
• Methadone
• Naltrexone

By Route of Administration:

• Oral
• Parenteral

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

About Future Market Insights, Inc.

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn | Twitter | Blogs